Technology Bundle ID

Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response

Linked ID
Lead Inventors
Ralph Tripp (CDC)
Deborah Moore (CDC)
Larry Anderson (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated diseases. More specifically, this technology entails administration of anti-substance P antibodies or anti-substance P antibody fragments to a subject in need, thereby inhibiting the activity of endogenous substance P.

Small molecule anti-inflammatory agents currently employed to treat inflammation frequently cause adverse side effects, such as gastrointestinal discomfort and decreased blood clotting efficiency. Use of steroid-based anti-inflammatory drugs may result in reduced adrenal gland function and generalized immune system inhibition. This technology specifically targets and alleviates substance P-induced hyper-inflammatory diseases, potentially avoiding the complications associated with other anti-inflammatory compounds. Blocking the activity of endogenous substance P potentially can be employed to prevent or treat a wide variety of diseases or syndromes caused in whole or part by an inflammatory response mediated by substance P. These include, but are not limited to, virus-mediated bronchiolitis including that mediated by respiratory syncytial virus, bacterial colitis, inflammation associated with chlamydial diseases, lung injury associated with staphylococcal enterotoxin B, inflammation due to cytomegalovirus or hepatitis B virus, sepsis, allergic diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, pancreatitis, inflammatory bowel disease, inflammation associated with multiple sclerosis, and rejection of allografts and other transplanted tissues or organs.
Commercial Applications
  • Treatment of pathogen induced inflammation, especially bronchiolitis
  • Prevention or lessening of adverse effects associated with other anti-inflammatory agents
Competitive Advantages
  • Useful for management of numerous inflammatory-related viral and/or bacterial infections
  • May reduce or circumvent adverse side effects associated with other small-molecule and/or steroid-based anti-inflammatory treatments

Request More Info

Licensing Contact: